PT - JOURNAL ARTICLE AU - Rosa Andres-Ejarque AU - Hira Bahadur Ale AU - Katarzyna Grys AU - Isabella Tosi AU - Shane Solanky AU - Chrysanthi Ainali AU - Zeynep Catak AU - Hemawtee Sreeneebus AU - Jake Saklatvala AU - Nick Dand AU - Emanuele de Rinaldis AU - Anna Chapman AU - Frank O. Nestle AU - Michael R. Barnes AU - Richard B. Warren AU - Nick J. Reynolds AU - Christopher E.M. Griffiths AU - Jonathan N. Barker AU - Catherine H. Smith AU - Paola Di Meglio AU - on behalf of the PSORT Consortium TI - Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis AID - 10.1101/2020.11.09.20228502 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.09.20228502 4099 - http://medrxiv.org/content/early/2020/11/12/2020.11.09.20228502.short 4100 - http://medrxiv.org/content/early/2020/11/12/2020.11.09.20228502.full AB - Biological therapies have transformed the management of psoriasis but clinical outcome is variable leaving an unmet clinical need for predictive biomarkers of response. To identify the immune determinants of response to the anti-TNF drug adalimumab and evaluate their predictive value, we performed in-depth immunomonitoring of blood immune cells of 67 psoriasis patients, before and during therapy. We assessed proximal TNF signaling events, by measuring NF-κB nuclear translocation and phosphorylation, and downstream effects, such as cell phenotype and function. Enhanced NF-κBp65 phosphorylation, induced by TNF and LPS in type-2 dendritic cells (DC) before therapy, significantly correlated with lack of clinical response after 12 weeks’ treatment. The heightened NF-κB activation was mechanistically linked to increased DC maturation in vitro and frequency of IL-17+T cells in the blood of non-responders before therapy. Moreover, lesional skin of non-responders contained more activated dermal DC and increased numbers of IL-17+T cells. sFinally, we identified and clinically validated LPS-induced NF-κBp65 phosphorylation before therapy as a predictive biomarker of non-response to adalimumab, with 100% sensitivity and 90.1% specificity in an independent cohort. Our study uncovers key molecular and cellular players underpinning adalimumab mechanisms of action in psoriasis and proposes a blood biomarker for predicting clinical outcome.Competing Interest StatementCA is an employee of DIGNOSIS Ltd. EdR and FON are currently employees of Sanofi. MRB has received honoraria and/or research grants from Janssen, Servier and Lilly RBW has received honoraria and/or research grants from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, Leo, Lilly, Novartis, Pfizer, Sanofi, Xenoport, and UCB. NJR has received research grants from GSK-Stiefel and Novartis; and other income to Newcastle University from Almirall, Amgen, Janssen, Novartis, Sanofi Genzyme Regeneron and UCB Pharma Ltd for lectures/attendance at advisory boards. CEMG reports grants and/or personal fees from AbbVie, Almirall, Amgen, BMS, Celgene, Galderma, Janssen, Leo Pharma, Lilly, Novartis, Sandoz and UCB Pharma. JNB has received honoraria and/or research grants from AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Leo, Lilly, Novartis, Samsung, Sun Pharma. CHS has received departmental research funding from AbbVie, GSK, Pfizer, Novartis, Regeneron, and Roche. PDM reports grants and/or personal fees from Janssen, Novartis, and UCB Pharma. All the other authors do not report any competing interest. Funding StatementSupported by the PSORT Consortium, which is in turn funded by a Medical Research Council (MRC) Stratified Medicine award (MR/L011808/1). Partners of the PSORT consortium are AbbVie, the British Association of Dermatologists, Becton Dickinson and Company, Celgene Limited, GlaxoSmithKline, Guy's and St Thomas' NHS Foundation Trust, Eli Lilly, Janssen Research & Development, King's College London, LEO Pharma, MedImmune, Novartis Pharmaceuticals UK, Pfizer Italy, the Psoriasis Association, Qiagen Manchester, Queen Mary University of London, the Royal College of Physicians, Sanquin Blood Supply Foundation, the University of Liverpool, the University of Manchester, and Newcastle University. We particularly acknowledge generous in kind support from the PSORT industrial partner Becton Dickson. All decisions concerning analysis, interpretation, and publication are made independently of any industrial contribution. This research was also supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London, the Newcastle NIHR Biomedical Research Centre, and the NIHR Manchester Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. The GTEx Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. ND is supported by Health Data Research UK (MR/S003126/1). NJR is supported by the Newcastle NIHR Biomedical Research Centre and the Newcastle NIHR Medtech and In vitro diagnostics Co-operative. CEMG and NJR are NIHR Senior Investigators.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:London Bridge research ethics committee (REC numbers: 14/LO/1685; 11/LO/1692; 06/Q0704/18; 13/EE/0241)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included in the manuscript